Premium
Estimation of Type‐Specific Neutralizing Antibody to Herpes Simplex Virus Type 2 in Uterine Cervical Cancer Patients by a New Absorption Method
Author(s) -
Kawana Takashi,
Yoshino Kamesaburo
Publication year - 1980
Publication title -
microbiology and immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.664
H-Index - 70
eISSN - 1348-0421
pISSN - 0385-5600
DOI - 10.1111/j.1348-0421.1980.tb02921.x
Subject(s) - herpes simplex virus , antibody , vero cell , neutralizing antibody , virology , titer , neutralization , virus , cervical cancer , biology , antibody titer , medicine , immunology , cancer
A simple method of estimating type‐specific neutralizing antibody to type 2 herpes simplex virus (HSV‐2) was devised with the use of the microneutralization system. Serially diluted serum was mixed in the well with a constant amount of type 1 virus (HSV‐1), and after 3 days' incubation at 37 C, the plate was irradiated with ultraviolet light. The absorbing HSV‐1 consisted of culture fluid plus an extract of infected Vero cells not especially concentrated. The well then received indicator HSV‐1 or HSV‐2, and after being left at 37 C for 1 hr a suspension of dispersed Vero cells was dropped into the wells, following our standard neutralization procedure. Preliminary tests with rabbit antisera showed that even a low level of HSV‐2 antibody was detected by this method, unless an exceptionally high titer of HSV‐1 antibody originally coexisted with the HSV‐2 antibody. Sera from acutely infected persons testified to the specificity of the antibody so detected. It was revealed by means of the new technique that the rate of HSV‐2 antibody was significantly higher in uterine cervical cancer patients than in control women. There was no correlation between the clinical stage of cervical cancer and the presence of HSV‐2 antibody.